IST effective against inflammation

Article

Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.

Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.

Paolo Mora, MD of the University of Parma, Italy and colleagues conducted a prospective, non-randomized study of patients with ocular inflammation (n=76; eyes, n=121) who, after 9±2 months of non-response to monotherapy, switched to a combined immunosuppressive treatment (IST) protocol in which all treatments (including steroids) were administered discontinuously for 43±15 months.

Complete inflammation control was achieved in 86% of patients; the rate of inflammatory events per patient was 0.78±1.13 in the first year of treatment, and the rare continued to decrease throughout the follow-up period. Mean best-corrected visual acuity (BCVA) increased to 0.24 logMAR after follow-up from 0.31 logMAR at baseline. Despite these visual improvements, patients' blood pressure and uric acid blood levels worsened significantly during the study period.

The researchers concluded that IST offers long-term improvements in the rate of inflammatory events and decreases the need for steroid treatment.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.